Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

被引：0
|
作者：
Middleton, M. R. [1 ]
Wermke, M. [2 ]
Calvo, E. [3 ]
Chartash, E. [4 ]
Zhou, H. [4 ]
Zhao, X. [4 ]
Niewel, M. [5 ]
Dobrenkov, K. [4 ]
Moreno, V. [6 ]
机构：
[1] Univ Oxford, Oncol, Oxford, England
[2] Univ Klinikum CG Carus, UCC Early Clin Trial Unit, Dresden, Germany
[3] Hosp Fdn Jimenez Diaz, Clin Res, START Madrid FJD, Madrid, Spain
[4] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, Clin, Munich, Germany
[6] Hosp Fdn Jimenez Diaz, Med Oncol, START Madrid FJD, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页数：1
相关论文
共 50 条
  • [41] INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors
    John F. Hilton
    Patrick A. Ott
    Aaron R. Hansen
    Zujun Li
    Matthen Mathew
    Cristina H. Messina
    Vimal Dave
    Xiao Ji
    Natalie O. Karpinich
    Steven Hirschfeld
    Marc Ballas
    Dan P. Zandberg
    Cancer Immunology, Immunotherapy, 73
  • [42] MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
    Vicier, C.
    Isambert, N.
    Cropet, C.
    Hamimed, M.
    Osanno, L.
    Legrand, F.
    Rouge, T. de La Motte
    Ciccolini, J.
    Goncalves, A.
    ESMO OPEN, 2022, 7 (06)
  • [43] INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors
    Hilton, John F.
    Ott, Patrick A.
    Hansen, Aaron R.
    Li, Zujun
    Mathew, Matthen
    Messina, Cristina H.
    Dave, Vimal
    Ji, Xiao
    Karpinich, Natalie O.
    Hirschfeld, Steven
    Ballas, Marc
    Zandberg, Dan P.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (03)
  • [44] Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
    Price, T. J.
    Prenen, H.
    Lugowska, I.
    Falchook, G. S.
    Monzon, J. G.
    Arkenau, H. T.
    Chawla, S. P.
    Hui, M. N.
    Kuboki, Y.
    Dziadziuszko, R.
    Ozawa, Y.
    Fernandez, M. E. Elez
    Lima, C. S. P. Rocha
    Subbiah, V.
    Tan, D. S. W.
    Wang, K.
    Hindoyan, A.
    Shi, W.
    Kistler, M.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2021, 32 : S1440 - S1442
  • [45] BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.
    Cousin, Sophie
    Blay, Jean-Yves
    Garcia, Irene Brana
    De Bono, Johann S.
    Le Tourneau, Christophe
    Moreno, Victor
    Trigo, Jose Manuel
    Hann, Christine L.
    Azad, Arun
    Im, Seock-Ah
    Ferron-Brady, Geraldine
    Datta, Antara
    Wu, Yuehui
    Horner, Thierry
    Kremer, Brandon Edward
    Dhar, Arindam
    O'Dwyer, Peter J.
    Shapiro, Geoffrey
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] A MULTICENTER OPEN-LABEL PHASE I/LB STUDY OF SO-C101 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED/METASTATIC SOLID TUMORS
    Marabelle, Aurelien
    Champiat, Stephane
    Garralda, Elena
    Hernando, Alberto
    Janku, Filip
    Raina, Anjali
    Sachse, Richard
    Bechard, David
    Krasnopolskaya, Inna
    Ferrara, Stefano
    LoRusso, Patricia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A483 - A483
  • [47] A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
    Hua, Y.
    Wang, C.
    Li, F.
    Han, Y.
    Zuo, D.
    Lv, Y.
    Peng, Y.
    Chen, J.
    Yuan, R.
    Zhang, F.
    Wang, Y.
    Wu, H.
    Zhou, G.
    Wang, S.
    Li, N.
    Lu, Y.
    Lin, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S677 - S677
  • [48] A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
    Voss, Martin H.
    Hierro, Cinta
    Heist, Rebecca S.
    Cleary, James M.
    Meric-Bernstam, Funda
    Tabernero, Josep
    Janku, Filip
    Gandhi, Leena
    Iafrate, A. John
    Borger, Darrell R.
    Ishii, Nobuya
    Hu, Youyou
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Chessex, Anne Vaslin
    Zanna, Claudio
    Flaherty, Keith T.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2699 - 2707
  • [49] A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
    George, Suzanne
    Heinrich, Michael C.
    Somaiah, Neeta
    Oppelt, Peter
    McLeod, Robert
    Nishioka, Satoshi
    Kundu, Madan G.
    Qian, Xiaozhong
    Kumar, Prasanna
    Laadem, Abderrahmane
    Lau, Yvonne
    Tran, Brittany P.
    Fallon, Maura
    Dosunmu, Ololade
    Shi, Julia
    Naito, Yoichi
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3659 - 3667
  • [50] A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Cosaert, Jan G. C. E.
    Falchook, Gerald Steven
    Jones, Suzanne Fields
    Strickland, Donald
    Greenlees, Carol
    Charlton, Julie
    MacDonald, Alexander
    Overend, Philip
    Adelman, Carrie
    Burris, Howard A.
    Pease, Elizabeth J.
    Patel, Gargi Surendra
    Wang, Judy Sing-Zan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345